搜索筛选:
搜索耗时4.4479秒,为你在为你在102,285,761篇论文里面共找到 15 篇相符的论文内容
发布年度:
Met-positive (Met+), locally advanced or metastatic non-small cell lung cancer (NSCLC) with epiderma
[会议论文] 作者：Yi-Long Wu,Keunchil Park,Lianzhe Xu,Peiqi Li,Andreas Johne,James Chih-Hsin Yang,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
...
Met-positive (Met+), locally advanced or metastatic non-small cell lung cancer (NSCLC) with epiderma
[会议论文] 作者：Yi-Long Wu,Keunchil Park,Lianzhe Xu,Peiqi Li,Andreas Johne,James Chih-Hsin Yang,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: A secondary mutation in the EGFR (ie, T790M) and amplification of the c-Met proto-oncogene are the main causes of resistance to EGFR tyrosine kinase inhibitors (eg, gefitinib) in EGFRm+ NSC...
Activity of the c-Met inhibitor tepotinib (MSC2156119J) in combination with gefitinib in Asian patie
[会议论文] 作者：Yi-long Wu,Keunchil Park,Dong-wan Kim,Ross a.Soo,Huiling Xiong,Cindy Li,Christian Ihling,James chih-hsin Yang,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: c-Met abnormalities can cause resistance to EGFR TKIs in EGFR mutant NSCLC patients (pts).The highly selective c-Met inhibitor tepotinib (MSC2156...
Phase Ⅱ trial comparing tepotinib + gefitinib with cisplatin + pemetrexed in Asian patients with gef
[会议论文] 作者：Yilong Wu,Keunchil Park,Dongwan Kim,Ross a.Soo,Cindy Li,Huiling Xiong,Christian Ihling,James chih-hsin Yang,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Background: The combination of the highly selective c-Met inhibitor tepotinib (MSC2156119J) + gefitinib was shown to be well tolerated and have antitumor activity possibly associated with c-Met-positi...
Activity of the c-Met inhibitor tepotinib (MSC2156119J) in combination with gefitinib in Asian patie
[会议论文] 作者：Yi-long Wu,Keunchil Park,Dong-wan Kim,Ross a.Soo,Cindy Li,Huiling Xiong,Christian Ihling,James chih-hsin Yang,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: c-Met abnormalities can cause resistance to EGFR TKIs in EGFR mutant NSCLC patients (pts).The highly selective c-Met inhibitor tepotinib (MSC2156119J) had promising activity in a phase Ⅰ tr...
Pemetrexed continuation maintenance: An effective tolerable strategy for treating nonsquamous non-sm
[会议论文] 作者：James Chih-Hsin Yang,Myung-Ju Ahn,Kazuhiko Nakagawa,Tomohide Tamura,Helen Barraclough,Sotaro Enatsu,Rebecca,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
...
Pemetrexed continuation maintenance: An effective tolerable strategy for treating nonsquamous non-sm
[会议论文] 作者：James Chih-Hsin Yang,Myung-Ju Ahn,Kazuhiko Nakagawa,Tomohide Tamura,Helen Barraclough,Sotaro Enatsu,Rebecca,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: A recent phase 3 study (PARAMOUNT) demonstrated that continuation maintenance therapy of pemetrexed is a new treatment paradigm for advanced nonsquamous NSCLC.The majority of patients enrol...
Safety and efficacy of the Asian subgroup of patients (pts) with EGFR-TKI-resistant advanced non-sma
[会议论文] 作者：Myung-Ju Ahn,Yuichiro Ohe,James Chih-Hsin Yang,Dong-Wan Kim,Sang-We Kim,Yuri Rukazenkov,Mireille Cantarini,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
...
Safety and efficacy of the Asian subgroup of patients (pts) with EGFR-TKI-resistant advanced non-sma
[会议论文] 作者：Myung-Ju Ahn,Yuichiro Ohe,James Chih-Hsin Yang,Dong-Wan Kim,Sang-We Kim,Yuri Rukazenkov,Mireille Cantarini,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: AZD9291 is an oral, potent, irreversible EGFR-TKI, selective for sensitizing (EGFRm+) and T790M resistance mutations, currently under investigation in an ongoing Phase Ⅰ study of pts with E...
Drug Exposure and Safety of Pemetrexed/platinum versus Other Platinum-based Doublets as First-line T
[会议论文] 作者：Shun Lu,Yi-long Wu,Ying Cheng,Cai-cun Zhou,Jie Wang,James Chih-Hsin Yang,Xiao-qing Zhang,Ping-hai Zhang,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
...
Utilizing Pemetrexed plus Platinum as First-line Treatment in East-Asian Elderly Patients with Advan
[会议论文] 作者：Shun ku,Yi-long Wu,Ying Cheng,Cai-cun Zhou,Jie Wang,James Chih-Hsin Yang,Ping-hai Zhang,Xiao-qing Zhang,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
...
Utilizing Pemetrexed plus Platinum as First-line Treatment in East-Asian Elderly Patients with Advan
[会议论文] 作者：Shun ku,Yi-long Wu,Ying Cheng,Cai-cun Zhou,Jie Wang,James Chih-Hsin Yang,Ping-hai Zhang,Xiao-qing Zhang,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: A meta-analysis was recently conducted in East-Asian advanced non-squamous non-small cell lung cancer (nsq-NSCLC) patients based on available individual patient data from three randomized p...
Drug Exposure and Safety of Pemetrexed/platinum versus Other Platinum-based Doublets as First-line T
[会议论文] 作者：Shun Lu,Yi-long Wu,Ying Cheng,Cai-cun Zhou,Jie Wang,James Chih-Hsin Yang,Xiao-qing Zhang,Ping-hai Zhang,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: Pemetrexed in combination with platinum has shown better efficacy and less toxicity than other standard first-line chemotherapies for patients with advanced non-squamous non-small cell lung...
Randomized trial of gefitinib with and without pemetrexed as first-line therapy in East-Asian patien
[会议论文] 作者：Jianxing He,Kazuhiko Nakagawa,Jin Hyoung Kang,Joo-Hang Kim,Tarun Puri,Xin Wang,Sotaro Enatsu,James Chih-Hsin Yang,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
目的： Pemetrexed (P) is the standard of care for non-squamous non-small cell lung cancer (NS NSCLC)， whereas epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)， such as gefitinib...
Phase Ⅲ trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the l
[会议论文] 作者：Caicun Zhou,Shukui Qin,Chengping Hu,Ki hyeong Lee,Young joo Min,Jin-hyoung Kang,Jong-seok Lee,James Chih-hsin Yang,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: Treatment options for pts with advanced SCC of the lung progressing after platinum-based chemotherapy are limited.Over expression of EGFR, other ErbB receptors and the dysregulation of thei...
相关搜索：
